Healthy Returns: Wegovy may reduce knee pain in patients with a type of arthritis and obesity [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
Subscribe here to receive future editions. Happy Thursday! New research showing additional health benefits of the weight loss drug Wegovy seems to crop up every week. This time around, Novo Nordisk 's blockbuster treatment helped reduce knee pain in patients with a type of arthritis and obesity, according to research published Wednesday in the New England Journal of Medicine. The study was funded by Novo Nordisk, which is conducting several studies on the other potential treatment uses of semaglutide, the active ingredient in Wegovy. The results of the 68-week trial could be a big deal for the Danish drugmaker: It could pave the way for regulatory approval of semaglutide for osteoarthritis, a degenerative joint disease that causes the cartilage and bone in your joints to break down over time. It would be yet another expansion of the accepted uses for the blockbuster drug. It's the most common type of arthritis and affects around 33 million people in the U.S., according to
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Semaglutide linked to reduced arthritis knee pain in people with obesity, study finds [MSNBC.com]MSNBC.com
- Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says [CNBC]CNBC
- Lilly Cuts Guidance on Disappointing Weight-Loss Drug Sales [BNN Bloomberg (Canada)]BNN Bloomberg
- Lilly Cuts Guidance on Disappointing Weight-Loss Drug Sales [Yahoo! Finance Canada]Yahoo! Finance Canada
- Lilly Cuts Guidance on Disappointing Weight-Loss Drug Sales [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 8/8/24 - Beat
NVO
Sec Filings
- 10/28/24 - Form 6-K
- 10/21/24 - Form 6-K
- 10/21/24 - Form 6-K
- NVO's page on the SEC website